Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels

Acta Oncol. 2020 Mar;59(3):257-259. doi: 10.1080/0284186X.2019.1695063. Epub 2019 Nov 22.

Authors

A Sibille¹, M Henket¹, J L Corhay¹, R Louis¹, B Duysinx¹

Affiliation

¹ CHU de Liège-Hôpital du Sart Tilman, Liège, Belgium.

PMID: 31755328
DOI: 10.1080/0284186X.2019.1695063

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
Carcinoma, Non-Small-Cell Lung / blood
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / pathology
Eosinophils / immunology*
Humans
Immunotherapy / methods*
Lung Neoplasms / blood
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor